
Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery
pharmafile | January 10, 2020 | News story | Medical Communications | Bayer, Exscientia, oncology
Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development, said: “The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures.”
Exscientia, a leading AI drug discovery company, will apply its Centaur Chemist AI drug discovery platform to discover and optimise drug candidates. Exscientia will initially work on three projects, with the targets agreed between them and Bayer.
Exescientia may be eligible to receive €240 million. This could include research payments and sales royalties.
Professor Andrew Hopkins, Chief Executive Officer of Exscientia, said: “We’re delighted to collaborate with Bayer, a globally recognised pharmaceutical company. Since our pioneering Nature papers demonstrating the automated design of small molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners.”
Conor Kavanagh
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …






